Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) to advance the development of botensilimab and balstilimab (BOT/BAL). The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.